Service Line:+1-315-239-3085
Address:FL-4, Building A5, International Enterprise Community, Tianjin, China
Email:[email protected]
Catalog Number | YR1428 |
---|---|
Product Name | Anti-Human CGRP Recombinant Antibody(Eptinezumab) |
Molecular Name | Eptinezumab |
Alias | Anti-CGRP Recombinant Antibody, Research Grade Eptinezumab |
CAS Number | 1644539-04-7 |
Target | CGRP[Homo sapiens] |
Isotype | IgG1 Kappa |
Clonity | Monoclonal |
Source | CHO Cells |
Size | 1mg, 5mg |
Concentration | 1mg/ml |
Purity | >95% as determined by SDS-PAGE |
Applications | ELISA, IHC, IF, IP, FCM, Inhib |
Buffer | PBS, pH7.5 |
Background | Eptinezumab, sold under the brand name Vyepti, is a medication for the preventive treatment of migraine in adults. It is a monoclonal antibody that targets calcitonin gene-related peptides (CGRP) alpha and beta. It is administered by intravenous infusion every three months. Eptinezumab-jjmr was approved for use in the United States in February 2020. |
Storage | It is recommended to aliquote and store at -20°C for long term storage. Avoid repeated freezing and thawing cycles. |
Note | This product is for research use only. |